Browsing category:

Antibacterial


Onychomycosis of the toenail as a result of either Trichophyton mentagrophytes or Trichophyton rubrum can be a painful and debilitating condition. Efinaconazole has emerged as a viable topical contender for treating this frustrating fungus, becoming an FDA approved topical therapy. Known as the brand name Jublia, which is marketed by Valeant Pharmaceuticals, this novel and[…]

Read More

Midstage trial data of a Pyrazinamide cocktail to treat TB has offered encouraging news for patients with the HIV infection. Coined PaMZ, this drug trio includes Pyrazinamide and two antibacterial drugs, with results going into the Phase III trial looking promising. The antibacterial drugs are PA-824, which was initially developed by the Novartis and the[…]

Read More

The end of June 2014 brought exciting news for Insmed’s liposomal Amikacin, known as the brand name Arikace, with a Breakthrough Status award from the FDA. Amikacin was specifically designated Breakthrough Status for treatment refractory nontuberculous mycobacterial lung disease in adult patients. As an inhaled antibiotic Amikacin is effectual for treating chronic nontuberculous mycobacterial lung[…]

Read More

Exciting news was announced at the end of May 2014 from Durata Therapeutics with the FDA approval of Dalbavancin, their novel antibiotic treatment. Known as the brand name Dalvance, the FDA nod for Dalbavancin meets a current need for new, safe and efficacious antibiotics. Dalbavancin is officially approved to treat skin structure and bacterial skin infections[…]

Read More

Approximately four million Americans undergo cataract surgery every year, so the recent FDA approval of Ketorolac and Phenylephrine on June 2, 2014 is timely and beneficial for many patients in the United States. Known as the brand name Omidria, the combination of Ketorolac and Phenylephrine to create an efficacious pupil-dilating agent has been deemed successful[…]

Read More

Daptomycin, recognized as the brand name antibiotic Cubicin, has a patent expiration of September 24, 2019. Cubist Pharmaceutical markets Cubicin and they recently released a report revealing surprisingly weak sales. Initially Cubist reported strong sales of Daptomycin for the first quarter of 2013, with an overall rise in their revenues due to this potent antibiotic.[…]

Read More

On March 25, 2014 Actavis and Valeant Pharmaceuticals announced the FDA approval of Metronidazole 1.3% gel for the antibiotic treatment of Bacterial Vaginosis. Bacterial Vaginosis, or BV, is an extremely common vaginal infection which commonly affects women between the ages of 15 and 44. An imbalance of normal bacteria in the vagina is the leading[…]

Read More

On February 10, 2104 a substantial financial deal was announced by Melinta Therapeutics involving their projected blockbuster antibiotic Delafloxacin. A whopping 70 million dollar Series 3 equity financing deal was revealed, with various investors taking part, including Vatera Healthcare Partners. This extraordinary financing will be appropriated largely to advance the continued development, assessment and eventual[…]

Read More

When penicillin was discovered in 1928 by Alexander Fleming no one knew quite how great of an impact this drug would make on the world. The actual use of penicillin to treat infection did not begin until the mid-1940s,  when a powdery form of this medication was developed by Howard Florey and Ernst Chain.  The[…]

Read More

Clindamycin & Clindamycin Phosphate, also known as the brand name Clindesse, faces a patent expiration on November 17, 2017. Clindamycin & Clindamycin Phosphate is a crucial treatment for Bacterial Vaginosis. With roughly 700,000 cases of Bacterial Vaginosis, also known as BV, in the US each year, this condition affects women of varying ages. Estimates suggest that[…]

Read More